MX2017013419A - Metodo para aumentar el porcentaje de las especies multimericas de fragmento de union a antigeno-fragmento variable de disulfuro (fab-dsfv) del anticuerpo monomerico. - Google Patents

Metodo para aumentar el porcentaje de las especies multimericas de fragmento de union a antigeno-fragmento variable de disulfuro (fab-dsfv) del anticuerpo monomerico.

Info

Publication number
MX2017013419A
MX2017013419A MX2017013419A MX2017013419A MX2017013419A MX 2017013419 A MX2017013419 A MX 2017013419A MX 2017013419 A MX2017013419 A MX 2017013419A MX 2017013419 A MX2017013419 A MX 2017013419A MX 2017013419 A MX2017013419 A MX 2017013419A
Authority
MX
Mexico
Prior art keywords
percentage
increasing
dsfv
antibody fab
monomeric antibody
Prior art date
Application number
MX2017013419A
Other languages
English (en)
Inventor
Philip Heywood Sam
Barry Wild Gavin
HANIF Razwan
John Le Page Christopher
Original Assignee
Ucb Biopharma Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Biopharma Sprl filed Critical Ucb Biopharma Sprl
Publication of MX2017013419A publication Critical patent/MX2017013419A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/624—Disulfide-stabilized antibody (dsFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención proporciona un método para aumentar el porcentaje del monómero en una composición de moléculas del anticuerpo expresadas de manera recombinante, caracterizado porque la molécula del anticuerpo comprende al menos un Fv con especificidad hacia un antígeno de interés que comprende un VH y un VL, en donde el VH y el VL están conectados directa o indirectamente por medio de uno o más enlazadores y son estabilizados por medio de un enlace de disulfuro entre los mismos, el método comprende: a) una etapa de conversión térmica manteniendo la composición que comprende la molécula del anticuerpo a una temperatura en el intervalo de 30 a 60 °C durante un periodo de al menos 1 hora, en donde la etapa a) es efectuada en la presencia de un agente reductor o después del tratamiento con un agente reductor.
MX2017013419A 2015-04-22 2016-04-22 Metodo para aumentar el porcentaje de las especies multimericas de fragmento de union a antigeno-fragmento variable de disulfuro (fab-dsfv) del anticuerpo monomerico. MX2017013419A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1506869.5A GB201506869D0 (en) 2015-04-22 2015-04-22 Method
PCT/EP2016/059050 WO2016170137A1 (en) 2015-04-22 2016-04-22 Method for increasing the percentage of monomeric antibody fab-dsfv multimeric species

Publications (1)

Publication Number Publication Date
MX2017013419A true MX2017013419A (es) 2018-02-09

Family

ID=53299018

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017013419A MX2017013419A (es) 2015-04-22 2016-04-22 Metodo para aumentar el porcentaje de las especies multimericas de fragmento de union a antigeno-fragmento variable de disulfuro (fab-dsfv) del anticuerpo monomerico.

Country Status (16)

Country Link
US (2) US10829565B2 (es)
EP (1) EP3286220A1 (es)
JP (1) JP6901402B2 (es)
KR (1) KR20170138551A (es)
CN (1) CN107683290B (es)
AU (1) AU2016251960A1 (es)
BR (1) BR112017022472A2 (es)
CA (1) CA2983537A1 (es)
CL (1) CL2017002677A1 (es)
CO (1) CO2017010845A2 (es)
EA (1) EA201792325A1 (es)
GB (1) GB201506869D0 (es)
IL (1) IL255094A0 (es)
MX (1) MX2017013419A (es)
SG (1) SG11201708430VA (es)
WO (1) WO2016170137A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
RS61808B1 (sr) * 2016-12-09 2021-06-30 Ose Immunotherapeutics Antitela i polipeptidi usmereni protiv cd127

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4741900A (en) 1982-11-16 1988-05-03 Cytogen Corporation Antibody-metal ion complexes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
US4877868A (en) * 1986-03-12 1989-10-31 Neorx Corporation Radionuclide antibody coupling
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
WO1990002809A1 (en) 1988-09-02 1990-03-22 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0546073B1 (en) 1990-08-29 1997-09-10 GenPharm International, Inc. production and use of transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
DK1471142T3 (da) 1991-04-10 2009-03-09 Scripps Research Inst Heterodimere receptor-biblioteker under anvendelse af fagemider
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
DE69233782D1 (de) 1991-12-02 2010-05-20 Medical Res Council Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
EP0733070A1 (en) 1993-12-08 1996-09-25 Genzyme Corporation Process for generating specific antibodies
ATE243745T1 (de) 1994-01-31 2003-07-15 Univ Boston Bibliotheken aus polyklonalen antikörpern
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
GB0202633D0 (en) * 2002-02-05 2002-03-20 Delta Biotechnology Ltd Stabilization of protein preparations
EP1570267B1 (en) 2002-12-03 2011-10-12 UCB Pharma, S.A. Assay for identifying antibody producing cells
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315450D0 (en) * 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
SI1644412T2 (sl) 2003-07-01 2018-11-30 Ucb Biopharma Sprl Modificirani fab fragmenti protiteles
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
SG156672A1 (en) 2004-10-22 2009-11-26 Amgen Inc Methods for refolding of recombinant antibodies
GB0425534D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Process for obtaining antibodies
US20070212703A1 (en) 2005-09-27 2007-09-13 Stemmer Willem P Proteinaceous pharmaceuticals and uses thereof
CN101583370A (zh) * 2005-09-27 2009-11-18 阿穆尼克斯公司 蛋白质药物及其用途
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
EP2014680A1 (en) 2007-07-10 2009-01-14 Friedrich-Alexander-Universität Erlangen-Nürnberg Recombinant, single-chain, trivalent tri-specific or bi-specific antibody derivatives
CN101842387B (zh) 2007-09-26 2014-05-07 Ucb医药有限公司 双特异性抗体融合物
US20090269343A1 (en) 2008-04-11 2009-10-29 Duke University Dual Specific Immunotoxin for Brain Tumor Therapy
CA2733782A1 (en) 2008-08-14 2010-02-18 Merck Sharp & Dohme Corp. Methods for purifying antibodies using protein a affinity chromatography
NZ591651A (en) * 2008-09-26 2012-12-21 Merck Sharp & Dohme High titer antibody production and culture media comprising glucose, soy or wheat hydrolsyate, amino acids, and other chemical compounds
CN105601745B (zh) * 2008-09-26 2020-09-08 Ucb医药有限公司 生物产品
ES2864956T3 (es) * 2009-04-30 2021-10-14 Ablynx Nv Procedimiento para la producción de anticuerpos de dominio
WO2011030107A1 (en) 2009-09-10 2011-03-17 Ucb Pharma S.A. Multivalent antibodies
GB201005063D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
GB0920127D0 (en) 2009-11-17 2009-12-30 Ucb Pharma Sa Antibodies
GB201000467D0 (en) 2010-01-12 2010-02-24 Ucb Pharma Sa Antibodies
GB201001791D0 (en) * 2010-02-03 2010-03-24 Ucb Pharma Sa Process for obtaining antibodies
GB201005064D0 (en) 2010-03-25 2010-05-12 Ucb Pharma Sa Biological products
US10472426B2 (en) 2010-03-25 2019-11-12 Ucb Biopharma Sprl Disulfide stabilized DVD-Ig molecules
BR112012026766B1 (pt) * 2010-04-20 2021-11-03 Genmab A/S Métodos in vitro para gerar um anticorpo igg heterodimérico, para a seleção de um anticorpo biespecífico, vetor de expressão, anticorpo igg heterodimérico, composição farmacêutica, e, uso de um anticorpo igg heterodimérico
BR112012027001A2 (pt) * 2010-04-23 2016-07-19 Genentech Inc produção de proteínas heteromultiméricas
US20140124448A1 (en) 2011-04-13 2014-05-08 Hans Huber IMMUNOAFFINITY SEPARATION MATERIALS COMPRISING ANTI-IgE ANTIBODY DERIVATIVES
KR102492792B1 (ko) 2011-10-11 2023-01-30 제넨테크, 인크. 이중특이적 항체의 개선된 어셈블리
UA112203C2 (uk) 2011-11-11 2016-08-10 Юсб Фарма С.А. Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
DK2776466T3 (da) * 2011-11-11 2017-11-20 Ucb Biopharma Sprl Albuminbindende antistoffer og bindingsfragmenter deraf
EP2822597A1 (en) 2012-03-09 2015-01-14 UCL Business Plc. Chemical modification of antibodies
GB201208370D0 (en) 2012-05-14 2012-06-27 Ucb Pharma Sa Antibodies
GB201223276D0 (en) * 2012-12-21 2013-02-06 Ucb Pharma Sa Antibodies and methods of producing same
WO2015046467A1 (ja) * 2013-09-27 2015-04-02 中外製薬株式会社 ポリペプチド異種多量体の製造方法
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct
GB201506869D0 (en) * 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
GB201506868D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method for protein purification
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
ES2843558T3 (es) 2015-08-17 2021-07-19 Lupin Ltd Proceso de replegamiento mejorado de fragmentos de anticuerpo

Also Published As

Publication number Publication date
JP2018515453A (ja) 2018-06-14
CN107683290A (zh) 2018-02-09
CA2983537A1 (en) 2016-10-27
CN107683290B (zh) 2022-01-04
EA201792325A1 (ru) 2018-04-30
AU2016251960A1 (en) 2017-11-02
JP6901402B2 (ja) 2021-07-14
GB201506869D0 (en) 2015-06-03
KR20170138551A (ko) 2017-12-15
US20180142039A1 (en) 2018-05-24
BR112017022472A2 (pt) 2018-07-17
WO2016170137A1 (en) 2016-10-27
US11834514B2 (en) 2023-12-05
CL2017002677A1 (es) 2018-03-23
SG11201708430VA (en) 2017-11-29
US20210079120A1 (en) 2021-03-18
CO2017010845A2 (es) 2018-03-20
US10829565B2 (en) 2020-11-10
EP3286220A1 (en) 2018-02-28
IL255094A0 (en) 2017-12-31

Similar Documents

Publication Publication Date Title
MX2017013419A (es) Metodo para aumentar el porcentaje de las especies multimericas de fragmento de union a antigeno-fragmento variable de disulfuro (fab-dsfv) del anticuerpo monomerico.
EA201791961A1 (ru) Антитела, специфичные к cd47 и pd-l1
EA201491571A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С АСИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
MX2022010324A (es) Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
PH12018550179A1 (en) Anti-pd-1 antibodies, method for producing same and method for using same
PH12016500943A1 (en) Aplnr modulatros and uses thereof
MY194994A (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
EA201491569A1 (ru) МОДИФИЦИРОВАННЫЕ БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА IgG4 С СИММЕТРИЧНОЙ ПОСЛЕДОВАТЕЛЬНОСТЬЮ
MY201701A (en) Optimized antibody compositions for treatment of ocular disorders
EA201690167A1 (ru) Гуманизованные или химерные антитела к cd3
PE20170665A1 (es) Anticuerpos anti-tau humanizados
PE20180499A1 (es) Anticuerpos de union a tau
MA32712B1 (fr) Anticorps anti-vegf/anti-ang-2 bispecifique
EA201792329A1 (ru) Способ мономеризации рекомбинантных молекул антител
EA201690171A1 (ru) Улучшенный способ получения моноклональных антител
PH12019502298A1 (en) Monoclonal antibody to pd-l1
MX2015005874A (es) Anticuerpos especificos del factor de crecimiento b derivados de plaquetas y composiciones y usos de estos.
PH12016501366A1 (en) Novel anti-baff antibodies
AR093803A1 (es) Composiciones y metodos de anticuerpos de marcaje de epo
UA115906C2 (uk) Fc-ФРАГМЕНТ ІМУНОГЛОБУЛІНУ IgG4, ЯКИЙ МАЄ МОДИФІКОВАНУ ШАРНІРНУ ДІЛЯНКУ
EA201691780A1 (ru) Наноструктурированный песок, способ получения наноструктурированного песка, способ разделения смеси загрязняющее вещество-вода с помощью наноструктурированного песка и дополнительные применения
GB201005064D0 (en) Biological products
MX2017004117A (es) Moleculas de enlace, especialmente anticuerpos, enlazadas a l1cam(cd171).
PE20171107A1 (es) Anticuerpos mejorados contra il-6
CL2016001028A1 (es) Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh.